Anbio BiotechnologyNNNN +2.88%24 EV-to-FCF is 361.23 as of Jul. 04, 2026, which is 147% above its 10-year median of 145.96. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 418 Medical Devices & Instruments companies, Anbio Biotechnology ranks worse than 95.93% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Anbio Biotechnology's Enterprise Value is $534.98 Mil.
Anbio Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $1.48 Mil. Therefore, Anbio Biotechnology's EV-to-FCF for today is 361.23.
The historical rank and industry rank for Anbio Biotechnology's EV-to-FCF or its related term are showing as below:
NNNN'
s EV-to-FCF Range Over the Past 10 Years
Min: -224.99 Med: 145.96 Max: 1071.79
Current: 361.23
During the past 5 years, the highest EV-to-FCF of Anbio Biotechnology was 1071.79. The lowest was -224.99. And the median was 145.96.
NNNN's EV-to-FCF is ranked worse than 95.93% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 23.12
vs NNNN: 361.23
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anbio Biotechnology's PE Ratio (TTM) for today is calculated as:
Anbio Biotechnology's share price for today is $12.46.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.147.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Anbio Biotechnology EV-to-FCF Related Terms
Anbio Biotechnology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's EV-to-FCF falls into.
Anbio Biotechnology's current Enterprise Value is $534.98 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $1.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a EV-to-FCF of 361.23 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anbio Biotechnology and its competitors. This is 147% above median its historical median of 145.96. According to the industry distribution chart, Anbio Biotechnology ranks #401 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 95.9%.
Is Anbio Biotechnology's EV-to-FCF too high?
Anbio Biotechnology's current EV-to-FCF of 361.23 is 147% above median its 10-year median of 145.96. The Medical Devices & Instruments industry median EV-to-FCF is 23.12. Anbio Biotechnology's value of 361.23 is 1462.4% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #401 out of 418 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's EV-to-FCF compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #401 out of 418 companies for EV-to-FCF. This places Anbio Biotechnology in the lower half of its industry. The industry median EV-to-FCF is 23.12. Anbio Biotechnology's value of 361.23 is 1462.4% above this benchmark. While the company's 10-year median is 145.96 vs. the industry median of 23.12, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.12, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current EV-to-FCF of 361.23 is 1462.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current EV-to-FCF is 361.23, which is 147% above median its own 10-year median of 145.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current EV-to-FCF of 361.23. The current EV-to-FCF is 361.23, which is 147% above median its 10-year median of 145.96 and 1462.4% above the Medical Devices & Instruments industry median of 23.12. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current EV-to-FCF is 361.23 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
